Crawford J, Caserta C, Roila F et al (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol. https://doi.org/10.1093/annonc/mdq195

Article  PubMed  Google Scholar 

Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 47(1):8–32. https://doi.org/10.1016/j.ejca.2010.10.013

Article  CAS  PubMed  Google Scholar 

Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(28):3199–3212. https://doi.org/10.1200/JCO.2015.62.3488

Article  CAS  PubMed  Google Scholar 

NCCN Clinical Practice Guidelines in Oncology. Hematopoietic growth factors Version 2. 2023

Yang BB, Kido A (2011) Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 50(5):295–306. https://doi.org/10.2165/11586040-000000000-00000

Article  CAS  PubMed  Google Scholar 

Morizane T, Yoshida M, Kojimahara N, et al (2014) Minds handbook for clinical practice guideline development 2014. Japan Council for Quality Health Care, Tokyo. https://minds.jcqhc.or.jp/s/developer_manual(in Japanese)

Kojimahara N, Nakayama T, Morizane T, et al (2017) Minds manual for guideline development 2017. Japan Council for Quality Health Care, Tokyo

Cesaro S, Nesi F, Tridello G et al (2013) A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant. PLoS ONE 8(1):e53252. https://doi.org/10.1371/journal.pone.0053252

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holmes FA, Jones SE, O’Shaughnessy J et al (2002) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 13(6):903–909. https://doi.org/10.1093/annonc/mdf130

Article  CAS  PubMed  Google Scholar 

Holmes FA, O’Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20(3):727–731. https://doi.org/10.1200/JCO.2002.20.3.727

Article  CAS  PubMed  Google Scholar 

Green MD, Koelbl H, Baselga J et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14(1):29–35. https://doi.org/10.1093/annonc/mdg019

Article  CAS  PubMed  Google Scholar 

Grigg A, Solal-Celigny P, Hoskin P et al (2003) Open-label, randomized study of pegfilgrastim vs daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 44(9):1503–1508. https://doi.org/10.1080/1042819031000103953

Article  CAS  PubMed  Google Scholar 

Siena S, Piccart MJ, Holmes FA et al (2003) A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep 10(3):715–724

CAS  PubMed  Google Scholar 

Vose JM, Crump M, Lazarus H et al (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 21(3):514–519. https://doi.org/10.1200/JCO.2003.03.040

Article  CAS  PubMed  Google Scholar 

Sierra J, Szer J, Kassis J et al (2008) A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer 10(8):195. https://doi.org/10.1186/1471-2407-8-195

Article  CAS  Google Scholar 

Fox E, Widemann BC, Hawkins DS et al (2009) Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. Clin Cancer Res 15(23):7361–7367. https://doi.org/10.1158/1078-0432.CCR-09-0761

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rifkin R, Spitzer G, Orloff G et al (2010) Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 10(3):186–191. https://doi.org/10.3816/CLML.2010.n.029

Article  CAS  PubMed  Google Scholar 

Spunt SL, Irving H, Frost J et al (2010) Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol 28(8):1329–1336. https://doi.org/10.1200/JCO.2009.24.8872

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang W, Jiang Z, Wang L et al (2015) An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy. Med Oncol 32(5):147. https://doi.org/10.1007/s12032-015-0537-7

Article  CAS  PubMed  Google Scholar 

Kubo K, Miyazaki Y, Murayama T et al (2016) A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma. Br J Haematol 174(4):563–570. https://doi.org/10.1111/bjh.14088

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martino M, Praticò G, Messina G et al (2006) Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 77(5):410–415. https://doi.org/10.1111/j.1600-0609.2006.00736.x

Article  CAS  PubMed  Google Scholar 

Martino M, Gori M, Tripepi G et al (2020) A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant. Ann Hematol 99(2):331–341. https://doi.org/10.1007/s00277-019-03901-w

Article  CAS  PubMed  Google Scholar 

Tadmor T, Levy I, Herishanu Y et al (2019) Primary peg-filgrastim prophylaxis versus filgrastim given “on demand” for neutropenia during therapy with cladribine for hairy cell leukemia. Leuk Res 82:24–28. https://doi.org/10.1016/j.leukres.2019.05.006

Article  CAS  PubMed  Google Scholar 

Kourlaba G, Dimopoulos MA, Pectasides D et al (2015) Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer 23(7):2045–2051. https://doi.org/10.1007/s00520-014-2555-y

Article  PubMed  Google Scholar 

Almenar D, Mayans J, Juan O et al (2009) Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain–results of the LEARN Study. Eur J Cancer Care (Engl) 18(3):280–286. https://doi.org/10.1111/j.1365-2354.2008.00959.x

Article  CAS  PubMed  Google Scholar 

Staber PB, Holub R, Linkesch W et al (2005) Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 35(9):889–893. https://doi.org/10.1038/sj.bmt.1704927

Article  CAS  PubMed  Google Scholar 

Gerds A, Fox-Geiman M, Dawravoo K et al (2010) Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 16(5):678–685. https://doi.org/10.1016/j.bbmt.2009.12.531

Article  CAS  PubMed  Google Scholar 

Henk HJ, Becker L, Tan H et al (2013) Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses. J Med Econ 16(1):160–168. https://doi.org/10.3111/13696998.2012.734885

Article  CAS  PubMed  Google Scholar 

Kubista E, Glaspy J, Holmes FA et al (2003) Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer 3(6):391–398. https://doi.org/10.3816/cbc.2003.n.003

Article  CAS  PubMed  Google Scholar